International Patent: MUTASYNTHESIS OF C17 AND C21 SUBSTITUTED ANSAMITOCINS FOR USE AS ANTIBODY-DRUG CONJUGATE (ADC) PAYLOADS

GENEVA, Oct. 30 -- REGENERON PHARMACEUTICALS, INC. filed a patent application (US2026/024995) for “MUTASYNTHESIS OF C17 AND C21 SUBSTITUTED ANSAMITOCINS FOR USE AS ANTIBODY-DRUG CONJUGATE (ADC) PAYLOADS”. With publication no. WO/2026/226848, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: A61P 35/00

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....